Rosetta Genomics appoints new CEO
This article was originally published in Clinica
MicroRNA-based molecular diagnostics specialist Rosetta Genomics has appointed Kenneth Berlin president and CEO. The Rehovot, Israel-based firm's board of directors has also recommended that Mr Berlin serve on the board. Mr Berlin was most recently employed as worldwide general manager at cellular and molecular cancer diagnostics company Veridex, where he worked since 2007. Before this, he had been employed by Johnson & Johnson since 1994, latterly as worldwide vice-president of franchise development for its subsidiary Ortho-Clinical Diagnostics.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.